Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:HALO
  • CUSIP: 40637H10
  • Web: www.halozyme.com
Capitalization:
  • Market Cap: $1.85404 billion
  • Outstanding Shares: 128,615,000
Average Prices:
  • 50 Day Moving Avg: $13.29
  • 200 Day Moving Avg: $13.01
  • 52 Week Range: $8.18 - $15.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.30
  • P/E Growth: -0.24
Sales & Book Value:
  • Annual Revenue: $133.76 million
  • Price / Sales: 13.01
  • Book Value: ($0.46) per share
  • Price / Book: -29.41
Profitability:
  • EBIDTA: ($92,040,000.00)
  • Net Margins: -86.80%
  • Return on Assets: -43.53%
Debt:
  • Debt-to-Equity Ratio: -3.15%
  • Current Ratio: 3.60%
  • Quick Ratio: 3.37%
Misc:
  • Average Volume: 1.18 million shs.
  • Beta: 2.2
  • Short Ratio: 17
 
Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, May, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. The company earned $29.60 million during the quarter, compared to analyst estimates of $30.79 million. The business's revenue was down 30.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) earnings per share. View Halozyme Therapeutics' Earnings History.

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?

7 brokerages have issued 12-month price targets for Halozyme Therapeutics' shares. Their predictions range from $6.75 to $20.00. On average, they expect Halozyme Therapeutics' share price to reach $14.63 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

  • Connie L. Matsui, Chairman of the Board
  • Helen I Torley, President, Chief Executive Officer, Director
  • Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
  • Mark J. Gergen J.D., Chief Operating Officer, Senior Vice President
  • Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
  • Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
  • Jean-Pierre Bizzari M.D., Independent Director
  • James M. Daly, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Kenneth J. Kelley, Independent Director

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.48%), Taylor Wealth Management Partners (0.13%), Creative Planning (0.09%), Sit Investment Associates Inc. (0.05%), Aperio Group LLC (0.02%) and Dixon Hubard Feinour & Brown Inc. VA (0.01%). View Institutional Ownership Trends for Halozyme Therapeutics.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners, Fisher Asset Management LLC and Sit Investment Associates Inc.. View Insider Buying and Selling for Halozyme Therapeutics.

Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Aperio Group LLC and Creative Planning. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $13.53.


MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $14.63 (8.09% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/23/2017Barclays PLCReiterated RatingOverweight$16.00LowView Rating Details
4/17/2017BMO Capital MarketsInitiated CoverageMarket Perform$14.00LowView Rating Details
3/30/2017Deutsche Bank AGBoost Price TargetBuy$15.00 -> $17.00LowView Rating Details
1/23/2017Piper Jaffray CompaniesReiterated RatingBuy$20.00N/AView Rating Details
1/6/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
11/8/2016Jefferies Group LLCReiterated RatingSell$6.75N/AView Rating Details
9/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
2017 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.28)($0.28)($0.28)
Q4 20171($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 81.37%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
Source:
DateHeadline
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2017
finance.yahoo.com - July 21 at 3:12 PM
americanbankingnews.com logoZacks: Analysts Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - July 16 at 10:48 AM
prnewswire.com logoInitiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy - PR Newswire (press release)
www.prnewswire.com - July 14 at 8:56 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter
www.americanbankingnews.com - July 14 at 12:16 PM
streetinsider.com logoHalozyme Therapeutics (HALO) Announces Initiation Of Clinical ... - StreetInsider.com
www.streetinsider.com - July 13 at 3:57 PM
finance.yahoo.com logoInitiation Of Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
finance.yahoo.com - July 13 at 3:57 PM
finance.yahoo.com logoInvestor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 11 at 12:23 AM
finance.yahoo.com logoHalozyme To Host Second Quarter 2017 Financial Results Conference Call
finance.yahoo.com - July 10 at 7:22 PM
finance.yahoo.com logoInvestor thought Martin Shkreli was like 'Rain Man' character because of his financial focus
finance.yahoo.com - July 10 at 7:22 PM
finance.yahoo.com logoFormer Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 8 at 11:17 AM
finance.yahoo.com logoMartin Shkreli worker called him 'mentally unstable,' threatened to expose lies by 'scam artist'
finance.yahoo.com - July 8 at 11:17 AM
finance.yahoo.com logoFormer officer of Martin Shkreli hedge fund filed SEC complaint against Shkreli while at fund
finance.yahoo.com - July 8 at 11:17 AM
reuters.com logoBRIEF-Halozyme Therapeutics, unit entered into first amendment to amended, restated lease with BMR-11388 ... - Reuters
www.reuters.com - July 7 at 6:02 AM
finance.yahoo.com logoMartin Shkreli's lawyer and 'cowboy' venture capitalist duel over value of horses and investments
finance.yahoo.com - July 7 at 6:02 AM
finance.yahoo.com logoFormer Shkreli employee says 'pharma bro' was deeply depressed after hedge fund 'imploded'
finance.yahoo.com - July 7 at 6:02 AM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 3 at 6:32 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - July 1 at 5:38 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : June 30, 2017
finance.yahoo.com - June 30 at 7:30 PM
prnewswire.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer Presented ... - PR Newswire (press release)
www.prnewswire.com - June 28 at 11:54 PM
finance.yahoo.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
finance.yahoo.com - June 28 at 6:54 PM
prnewswire.com logoDance Biopharm Appoints Steve Thornton to Board of Directors
www.prnewswire.com - June 27 at 5:48 PM
finance.yahoo.com logoHalozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets
finance.yahoo.com - June 26 at 7:23 PM
finance.yahoo.com logoETFs with exposure to Halozyme Therapeutics, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 7:23 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 6:44 PM
prnewswire.com logoFDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE ... - PR Newswire (press release)
www.prnewswire.com - June 23 at 3:40 PM
americanbankingnews.com logoBarclays PLC Reiterates "Overweight" Rating for Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - June 23 at 9:32 AM
streetinsider.com logoHalozyme (HALO) Pleased by FDA Approval of Genentech's RITUXAN HYCELA
www.streetinsider.com - June 23 at 2:58 AM
finance.yahoo.com logoFDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology
finance.yahoo.com - June 23 at 2:58 AM
americanbankingnews.com logo$33.11 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 22 at 12:42 PM
americanbankingnews.com logo-$0.25 EPS Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - June 20 at 8:07 AM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : June 19, 2017
finance.yahoo.com - June 19 at 12:40 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - June 16 at 10:34 PM
nasdaq.com logoNotable Friday Option Activity: FINL, X, HALO
www.nasdaq.com - June 16 at 6:24 PM
finance.yahoo.com logoETFs with exposure to Halozyme Therapeutics, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 6:24 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 11:50 AM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Short Interest Update
www.americanbankingnews.com - June 12 at 7:14 AM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 6 at 6:23 PM
fool.com logoWhy Halozyme Therapeutics Inc. Sank 16.5% in May - Motley Fool
www.fool.com - June 6 at 6:03 PM
prnewswire.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO - PR Newswire (press release)
www.prnewswire.com - June 5 at 3:34 PM
finance.yahoo.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
finance.yahoo.com - June 4 at 5:45 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 1:04 PM
americanbankingnews.com logoZacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - May 26 at 11:57 AM
americanbankingnews.com logoZacks: Brokerages Expect Halozyme Therapeutics, Inc. (HALO) to Post -$0.25 EPS
www.americanbankingnews.com - May 25 at 12:20 AM
prnewswire.com logoHalozyme Therapeutics Announces Completion Of Public Offering And Full ...
www.prnewswire.com - May 24 at 5:28 PM
finance.yahoo.com logoHalozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - May 24 at 5:28 PM
seekingalpha.com logoHalozyme: PEGPH20 Clinical Development Progress Does Not Yet Translate To Value
seekingalpha.com - May 23 at 5:12 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017
finance.yahoo.com - May 22 at 11:09 AM
streetinsider.com logoHalozyme Therapeutics (HALO) Prices 10M Share Offering at $12.50/Sh
www.streetinsider.com - May 20 at 10:31 PM
nasdaq.com logoMid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - May 19 at 10:24 PM
fool.com logoHalozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% - Motley Fool
www.fool.com - May 19 at 10:24 PM

Social

Chart

Halozyme Therapeutics (HALO) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff